Overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 Conference. | June 4, 2023
- CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of. | June 3, 2023
Partial responses observed in 5 of 19 evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib in heavily pretreated populationPartial response observed in 1 of. | May 25, 2023